Abstract: The invention relates to multimers such as tetramers of polypeptides and tetramers and octamers of effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides.

Abstract: The invention relates to multimers such as tetramers of polypeptides and tetramers and octamers of effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides.

Abstract: The invention relates to multimers such as tetramers of polypeptides; and tetramers, octamers, dodecamers and hexadecamers of epitopes or effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides.

Abstract: A carrier to which is attached a peptide and DNA encoding the peptide, wherein the peptide includes at least one non-natural amino acid and/or wherein the peptide has a constrained secondary structure; or a carrier to which is attached ?2 microglobulin, a peptide, and DNA encoding the peptide, said carrier not bearing an MHC or MHC-like molecule.

Abstract: The invention relates to multimers such as tetramers of polypeptides and tetramers and octamers of effector domains, such as antigen binding sites (eg, antibody or TCR binding sites that specifically bind to antigen or pMHC, or variable domains thereof) or peptides such as incretin, insulin or hormone peptides.

Abstract: A carrier to which is attached a peptide and DNA encoding the peptide, wherein the peptide includes at least one non-natural amino acid and/or wherein the peptide has a constrained secondary structure; or a carrier to which is attached ?2 microglobulin, a peptide, and DNA encoding the peptide, said carrier not bearing an MHC or MHC-like molecule.

Abstract: A carrier to which is attached a peptide and DNA encoding the peptide, wherein the peptide includes at least one non-natural amino acid and/or wherein the peptide has a constrained secondary structure; or a carrier to which is attached ?2 micro-globulin, a peptide, and DNA encoding the peptide, said carrier not bearing an MHC or MHC-like molecule.

Abstract: The present invention provides a method of screening method small-molecule candidate therapeutics capable of inhibiting or interfering with intracellular protein-protein interactions, such as cancer associated oncogenic protein interactions and in particular RAS and LMO2 protein-protein interactions. The present invention also provides methods and assays for rationalized drug design based on identifying small molecular weight protein-protein interaction inhibitor molecules that emulate antibody therapeutics products.

Abstract: Substances are provided that are capable of modulating angiogenesis mediated by Lmo2 or a functionally related polypeptide, which substance binds to Lmo2 and/or a functionally related polypeptide, or alters the expression of Lmo2 or a functionally related polypeptide in a cell. Assay methods are provided for identifying such substances.

Abstract: The invention relates to a method for generating a non-human animal model of a chromosomal rearrangement, comprising creating a transgenic non-human mammal expressing a site-specific recombinase under the control of a cell type specific promoter, and having sites recognized by the recombinase present in its genome such that a chromosomal rearrangement is catalysed by the recombinase.

Abstract: Substances are provided that are capable of modulating angiogenesis mediated by Lmo2 or a functionally related polypeptide, which substance binds to Lmo2 and/or a functionally related polypeptide, or alters the expression of Lmo2 or a functionally related polypeptide in a cell. Assay methods are provided for identifying such substances.

Abstract: Substances are provided that are capable of modulating angiogenesis mediated by Lmo2 or a functionally related polypeptide, which substance binds to Lmo2 and/or a functionally related polypeptide, or alters the expression of Lmo2 or a functionally related polypeptide in a cell. Assay methods are provided for identifying such substances.

Abstract: The present invention relates to a crystal structure for the AML1 Runt domain and/or CBF&bgr;. In particular, the present invention relates to a crystal structure for an AML1 Runt domain:CBF&bgr;, complex and a ternary AML1 Runt domain:CBF&bgr;:DNA complex; and the use of the crystal structures to identify ligands capable of binding to the AML1 Runt domain and/or CBF&bgr;, and/or capable of modulating the DNA-binding capacity of the AML1 Runt domain.

Abstract: We describe a method of inducing a cell to generate a detectable signal. The method comprises the steps of providing a cell comprising an entity and providing a first reporter and a second reporter, in which a stable interaction of the first reporter with the second reporter leads to generation of a detectable signal. The first reporter and the second reporter are allowed to bind to the entity, such that binding of the reporters to the entity leads to stable interaction of the first reporter with the second reporter and generation of a signal. The signal is preferably the activation of a cell killing mechanism.